이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고위험 미만성 대형 B세포 림프종 환자 치료를 위한 론카툭시맙 테시린 및 리툭시맙 후 DA-EPOCH-R

2026년 11월 10일 업데이트: University of California, Davis

이전에 치료받지 않은 고위험 미만성 거대 B세포 림프종에서 Loncastuximab Tesirine 및 Rituximab(Lonca-R)에 이어 DA-EPOCH-R에 대한 2상 연구

This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To obtain a preliminary estimate of the anti-tumor activity of loncastuximab tesirine and rituximab (lonca-R) in newly diagnosed double-expressor lymphoma (DEL) and double-hit lymphoma (DHL).

SECONDARY OBJECTIVES:

I. To obtain additional efficacy measures of lonca-R in newly diagnosed DEL and DHL.

II. To assess safety and tolerability of lonca-R followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone (DA-EPOCH-R) as coded by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

OUTLINE:

Patients receive rituximab intravenously (IV), loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone orally (PO), and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and computed tomography (CT) or positron emission tomography (PET)/CT at screening, throughout the study, and during follow up.

연구 유형

중재적

등록 (추정된)

24

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, 미국, 92037
        • UC San Diego Moores Cancer Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Histologically or cytologically confirmed untreated DEL and DHL diffuse large B-cell lymphoma (DLBCL) meeting the World Health Organization (WHO) criteria for DEL - MYC greater than 40% and BCL2 greater than 50% by immunohistochemistry, or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit and/or triple-hit are included)

  • Measurable disease by CT or PET/CT scan, with one or more sites of disease >= 1.5 cm in longest dimension

  • Age >= 18 years at time of consent

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Life expectancy >= 6 months

  • Leukocytes >= 2,500/uL

  • Absolute neutrophil count >= 1,000/uL

  • Platelets >= 100,000/uL

  • Hemoglobin >= 8 g/dL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)

  • Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)

  • Creatinine clearance >= 30 mL/min by Cockcroft-Gault

  • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)

  • Transthoracic echocardiography (TTE) or multigated acquisition scan (MUGA) ejection fraction greater than 40%

  • Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 7 months after the last dose of study drug

  • Ability to understand and the willingness to sign a written informed consent document

  • Human immunodeficiency virus (HIV) infected patients:

    • No history of acquired immunodeficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination anti-retroviral therapy (ART)
    • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
    • At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3
    • At the time of study entry, the HIV viral load must be undetectable by standard laboratory assay
    • During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV positive (+) status
    • No history of non-adherence to ART and willing to adhere to ART while on study
    • Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed

Exclusion Criteria:

  • Current/ prior use of:

    • Lymphoma treatment, except for:

      • 1 cycle of DA-EPOCH-R or rituximab, cyclophosphamide, doxorubicin (Adriamycin) vincristine (Oncovin) and prednisolone (R-CHOP)
      • Radiotherapy > 2 weeks of initiating study treatment
      • Nitrosoureas or mitomycin C > 6 weeks of initiating study treatment
      • Steroid treatment for DLBCL or steroid monotherapy to stabilize disease while awaiting fluorescence in situ hybridization (FISH)
      • Other cancer therapies (e.g., prostate, breast hormonal-based therapy) per the principal investigator's discretion
    • Anthracycline greater than 50 mg/m^2 (total lifetime) for a prior malignancy

    • Complementary and alternative medications (CAM) within 1 week prior to initiating study treatment

    • Treatment with any other investigational agent for any indication within 3 weeks prior to initiating study treatment

    • Loncastuximab tesirine or rituximab with progression within 6 months of initiating study treatment

    • Oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible

    • Live, attenuated influenza vaccine within 4 weeks prior to initiating study treatment

  • Immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor, such as anti-tumor necrosis factor [TNF] agents) within 14 days prior to initiating study treatment. The following are exceptions to this criterion:

    • Steroids
    • Bisphosphonate therapy for symptomatic hypercalcemia or for other reasons (e.g., bone metastasis or osteoporosis)
  • Known uncontrolled central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement

  • History of hypersensitivity to anti-CD19 antibodies, loncastuximab tesirine, or any agents used in DA-EPOCH-R

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study

  • Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)

  • Breastfeeding or pregnancy

  • Clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; or inherited liver disease

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • Documented eczema, psoriasis, or lichen simplex chronicus of vitiligo with dermatologic manifestations (e.g., patients with psoriatic arthritis would be excluded), unless the following apply:

    • Affected skin covers less than 10% of body surface area (BSA)
    • Disease is well controlled at baseline and only requires low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
    • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • Known active tuberculosis (TB)

  • Severe infections within 4 weeks prior to initiating study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

  • Major surgical procedure within 28 days prior to initiating study treatment or anticipation of need for a major surgical procedure during the course of the study

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (Lonca-R, DA-EPOCH-R)

Patients receive rituximab IV, loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone PO, and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and CT or PET/CT at screening, throughout the study, and during follow up.

Given IV

다른 이름들:
  • 사이톡산
  • CTX
  • (-)-시클로포스파미드
  • 2H-1,3,2-옥사자포스포린, 2-[비스(2-클로로에틸)아미노]테트라하이드로-, 2-옥사이드, 일수화물
  • 칼록산
  • 시클로포스파미다
  • 시클로포스파마이드
  • 시클록살
  • 클라펜
  • CP 일수화물
  • CYCLO 셀
  • 사이클로블라스틴
  • 사이클로포스팜
  • 사이클로포스파미드 일수화물
  • 사이클로포스파미둠
  • 시클로포스판
  • 사이클로포스판
  • 시클로포스파늄
  • 사이클로스틴
  • 사이토포스판
  • 포스파세론
  • 제녹살
  • 제눅살
  • 레독시나
  • 미톡산
  • 네오사르
  • 리바이뮨
  • 실클로포스파미드
  • WR-138719

Given PO

다른 이름들:
  • 델타손
  • 오라소네
  • .delta.1-코르티손
  • 1, 2-디하이드로코르티손
  • 아다손
  • 코탄실
  • 다코르틴
  • 데코르틴
  • 데코티실
  • 데코턴
  • 델타 1-코르티손
  • 델타 돔
  • 델타코르텐
  • 델타코르티손
  • 델타데히드로코르티손
  • 델티슨
  • 델타
  • 이코노손
  • 리사코트
  • 메프로소나-F
  • 메타코르탄드라신
  • 메티코르텐
  • 오피솔로나
  • 파나코트
  • 파나솔-S
  • 파라코트
  • 페리고 프레드니손
  • 프레드
  • 프레디코르
  • 앞머리
  • 프레드니센-M
  • 프레드니코트
  • 프레드니딥
  • 프레드니롱가
  • 예측
  • 프레드니손 인텐솔
  • 프레드니소눔
  • 프레드니톤
  • 프로미펜
  • 라요스
  • 세르비손
  • SK-프레드니손

Given IV

다른 이름들:
  • 아드리아블라스틴
  • 하이드록시다우노마이신
  • 하이드록실 다우노루비신
  • 하이드록실다우노루비신

Given IV

다른 이름들:
  • 리툭산
  • 맙테라
  • ABP 798
  • BI 695500
  • C2B8 단클론항체
  • 키메라 항-CD20 항체
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8 단클론항체
  • 단클론항체 IDEC-C2B8
  • PF-05280586
  • 리아브니
  • 리툭시맙 ABBS
  • 리툭시맙 ARRX
  • 리툭시맙 바이오시밀러 ABP 798
  • 리툭시맙 바이오시밀러 BI 695500
  • 리툭시맙 바이오시밀러 CT-P10
  • 리툭시맙 바이오시밀러 GB241
  • 리툭시맙 바이오시밀러 IBI301
  • 리툭시맙 바이오시밀러 JHL1101
  • 리툭시맙 바이오시밀러 PF-05280586
  • 리툭시맙 바이오시밀러 RTXM83
  • 리툭시맙 바이오시밀러 SAIT101
  • 리툭시맙 바이오시밀러 SIBP-02
  • 리툭시맙 바이오시밀러 TQB2303
  • 리툭시맙 PVVR
  • 리툭시맙-abbs
  • 리툭시맙-arrx
  • 리툭시맙-pvvr
  • RTXM83
  • 루시언스
  • 트룩시마

Given IV

다른 이름들:
  • VCR
  • 류로크리스틴
  • 빈크리스틴

Given IV

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16

Given IV

다른 이름들:
  • 진론타
  • ADCT-402
  • 항-CD19 PBD-컨쥬게이트 ADCT-402
  • 론카툭시맙 테시린-필

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Complete response rate
기간: First dose through cycle 2 (1 cycle = 3 weeks)

Evaluated per 2014 Lugano criteria. An exact 95% confidence interval will be calculated.

First dose through cycle 2 (1 cycle = 3 weeks)

2차 결과 측정

결과 측정
측정값 설명
기간
Overall survival rate
기간: First dose to off study, assessed up to 3 years

Will be estimated using the product-limit of Kaplan and Meier.

First dose to off study, assessed up to 3 years
Relapse/progression free survival
기간: First dose (cycle 1 day 6 rituximab dose) until relapse/progression or off study, whichever occurs first, assessed up to 3 years

Will be estimated using the product-limit of Kaplan and Meier.

First dose (cycle 1 day 6 rituximab dose) until relapse/progression or off study, whichever occurs first, assessed up to 3 years
Overall response rate (complete response + partial response)
기간: First dose through cycle 2 (1 cycle = 3 weeks)

Defined as the proportion of participants who have partial or complete response from the start of study treatment through completion of 2 cycles. Evaluated per 2014 Lugano criteria. An exact 95% confidence interval will be calculated.

First dose through cycle 2 (1 cycle = 3 weeks)
Incidence of adverse events
기간: First dose through 30 days post last dose

Will evaluate the number of participants experiencing treatment-related adverse events, classified by severity and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Observed toxicities will be summarized by type (organ affected or laboratory determination), severity, date of onset, duration, and attribution.

First dose through 30 days post last dose

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Joseph M Tuscano, University of California, Davis

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 5월 24일

기본 완료 (추정된)

2027년 5월 1일

연구 완료 (추정된)

2027년 12월 15일

연구 등록 날짜

최초 제출

2022년 10월 10일

QC 기준을 충족하는 최초 제출

2022년 10월 27일

처음 게시됨 (실제)

2022년 10월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다